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Background." Role of endoscopic sphincterotomy (ES) in high risk patients with choledocholithiasis is
established but its role in good risk patients is unclear.
Design: A prospective randomized trial ofendoscopic sphincterotomy followed by surgery (ES + S) versus
surgery alone (SA) in good risk patients with choledocholithiasis.
Setting: A tertiary level referral hospital in north India; July 1991 to October 1993.
Patients and methods: Thirty three out of 60 patients with choledocholithiasis were found suitable for
randomization- 16 were randomised to ES+S group and 17 to SA group.
Results: Common bile duct clearance was achieved in 11/13 (85%) patients in ES+S group and in 13/15
(87%) in SA group. Major complications occurred in 4/13 (31%) patients in ES+S group and 3/16 (19%)
patients in SA group. These differences were not statistically significant, but patients in ES+S group were
exposed to morbidity twice, procedure related morbidity ofES being 23%. No significant differences were
observed in hospital stay and cost of treatment.
Conclusions: Results of this trial do not support use of precholecystectomy ES in good risk patients with
choledocholithiasis, since it did not offer any advantage over surgery alone.
KEY WORDS" Cholelithiasis common bile duct calculi sphincterotomy
endoscopic retrograde cholangiopancreatography.
INTRODUCTION
Endoscopic sphincterotomy (ES) has gained wide and
universal acceptance for management of choledocho-
lithiasis in postcholecystectomy patients and in high
risk patients with gallbladder (GB) in situ. ES has also
become the treatment of choice in patients with acute
cholangitis and pancreatitis due to gallstones. How-
ever, no clear guidelines are available regarding the
role of ES in good risk patients with choledo-
cholithiasis andGB in situ. Endoscopic removal ofthe
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common bile duct (CBD) stones followed by chole-
cystectomy as an alternative to GB and CBD surgery
has not been properly evaluated so far. Conflicting
23 reports have appeared supporting’ as well as oppos-
ing4’5 routine use ofES in these patients.
We conducted a prospective randomized trial com-
paring ES followed by surgery with surgery alone in
good risk patients with choledocholithiasis and report
the results.
PATIENTS AND METHODS
Between July 1991 and October 1993, 420 patients
with gallstone disease were seen in the Department of
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Surgical Gastroenterology at the Sanjay Gandhi Post-
Graduate Institute of Medical Scienes, Lucknow- a
tertiary level referral hospital in north India where
gallstone disease in common. Sixty out of these 420
patients were suspected to have choledocholithiasis
after clinical history and examination, biochemical
tests and ultrasonography (US). The suspicion of
choledocholithiasis was based on the presence of one
or more ofthe following criteria: total serum bilirubin
greater than 34.2 umol/L (n 8), serum alkaline
phosphatase greater than 235 IU/L (normal 35-125
IU/L) (n 18), CBD diameter greater than 10 mm
(n 18) and probable CBD stone (n 25) on US.
All 60 patients underwent endoscopic retrograde
cholangiopancreaticography (ERCP), under cover of
prophylactic antibiotics, before randomization. The
predetermined exclusion criteria were: i) elderly and
frail patient (n 1), ii) unsuitability to undergo major
surgery (n 0), iii) pregnancy (n 0), iv) patients pre-
senting with acute cholangitis and septicaemia (n 9),
v) failure to cannulate the CBD at ERCP (n 3), and
vi) stone larger than 15 mm (n 12). Two patients
were found not to have CBD stones on ERCP and
were excluded from the trial. A total of 27 patients
were thus excluded.
Following ERCP, the remaining 33 patients were
randomized into two groups by drawing sealed enve-
lopes that contained computer-generated random as-
signments. In the ES+S group, ES was undertaken at
the same time as ERCP. Clearance of the CBD was
achieved by basket retrievel or by subsequent sponta-
neous passage of calculi and a clear CBD was docu-
mented in all patients prior to surgery. Surgery in these
patients was scheduled on elective basis within 6 weeks
after ES. In the SA group, surgery was undertaken on
the next available operating list. CBD exploration was
performed in conventional fashion; choledochoscopy
(n 6) was employed at the discretion ofthe operating
surgeon.
The two groups were compared according to clini-
cal features and biochemical parameters (Table 1).
Cases were analyzed according to ’intention to treat’
policy. Outcome in every case was assessed in terms of
mortality, morbidity (major and minor), length of
hospital stay and the overall cost of treatment. Infor-
mation about hospital charges was obtained directly
from the hospital finance office while details of addi-
tional expenditure on drugs etc were taken from the
patients or their attendants.
Fisher’s exact test was used for comparison of clini-
cal parameters, success of treatment and morbidity.
Student’s t test was used to compare haematological
Table 1 Comparison of clinical features and biochemical para-
meters in two groups
ES + S group SA group P value
(n=13) (n=16)
Clinicalfeatures
Age (Years)* 42 (20-60) 46 (24-75) 0.55
Pain (%) 13 (100%) 15 (94%) 1.00
Jaundice(%) 5 (38%) 4 (25%) 0.68
Fever (%) 4 (31%) 4 (25%) 1.00
Acute cholangitis (%) 4 (31%) 4 (25%) 1.00
Biochemicalparameters*
nb (g/L) 114 (90-130) 108 (72-134) 0.11
TLC x 103/cumm 7.7 (3.3-12.0) 7.4 (3.5-12.0)0.36
Bilirubin (umol/L) 31 (6.8-118) 12 (3.4-111) 0.22
SAP(IU/L) 255 (57-978) 300 (57-650)0.46
SGOT (IU/L) 50 (11-292) 57 (08-212) 0.29
SGPT(IU/L) 64 (11-276) 58 (19-213)0.49
Albumin(g/L) 40 (27-50) 42 (35-52)0.18
Creatinine (umol/L) 80 (53-106) 80 (53-124) 0.24
* mean (range).
ES+S endoscopic sphincterotomy followed by surgery, SA-sur-
gery alone, Hb- haemoglobin, TLC -total leucocyte count, SAP
serum alkaline phosphatase, SGOT-serum glutamate oxalate
transaminase, SGPT-serum glutamate pyruvate transaminase.
and biochemical parameters and hospital stay and
cost of treatment.
RESULTS
Thirty three out of 60 (55%) patients with
choledocholithiasis could be entered into the trial.
Sixteen patients were randomized to ES+S group and
17 to SA group. The two groups were comparable with
respect to clinical features and biochemical param-
eters (Table I).
ES+S Group (n=16)
Thirteen patients completed treatment; three patients
were excluded from analysis because two did not com-
plete treatment and one was found to have carcinoma
of the gall bladder at surgery.
Successful clearance oftheCBD was achieved in 11/
13 (85%) patients. Elective cholecystectomy alone was
performed in 10 patients. Cholecystectomy with CBD
exploration was performed in three patients- in two
patients because of failure ofES to clear the CBD and
in one patient who refused to undergo check ERCP
since he had bleeding following ES.
The overall morbidity was 5/13 (39%) major mor-
bidity occurred in three patients (23%) following ES.
Two patients had acute cholangitis, one ofwhom alsoMANAGEMENT OF CHOLEDOCHOLITHIASIS 147
had septicaemia and major upper gastrointestinal
bleed and one had an attack of acute pancreatitis. All
complications were managed successfully by con-
servative measures. Major morbidity after elective
cholecystectomy occurred in two patients who had
chest infection and major wound infection; one of
these patients had acute cholangitis after ES while the
other had uneventful ES. Major complications thus
occurred in 4/13 (31%) patients. Minor complications
Table 2 Results in two groups
ES+S group SA group
No of patients
No of patients who
completed treatment 13 16
No of patients analysed 13 15
CBD cleared 11 (85%) 13 (87%)
Morbidity 5 (39%) 5 (31%)
major 4 (31%) 3 (19%)
Hospital stay (days) 10.6 (6-18) 11.3 (6-24)
3 (19%)
Rs 4,305
(US $135)
ES + S endoscopic sphicterotomy followed by surgery;
SA surgery alone; Rs Rupees.
16 17
occurred in 1/13 (8%) patient. The mean length of No of patientsrequiring
hospital stay was 10.6 days (range 6-18 days) but five second admission 5 (39%)
patients needed admission twice for completion of Cost of treatment Rs4,748
treatment. The number of days between ES and
(us$148)
cholecystectomy varied from to 47 days with median
of 20 days. The mean cost of overall treatment was
Rupees 4,748. (US $148 approximately).
SA Group (n=l 7)
Sixteen patients completed treatment. One patient
who was found to have carcinoma of the gall bladder
at surgery was excluded. CBD was explored in 15
patients; one patient developed actue cholecystitis and
empyema of the gall bladder following ERCP and
underwent emergency cholecystostomy. On subse-
quent cholecystocholangiogram 8 weeks later CBD
was found to be stone free and hence he did not require
CBD exploration.
Complete duct clearance was achieved in 13/15
(87%) patients. Two (13%) patients had retained
stones which were later managed successfully with ES.
The overall morbidity was 5/16 (31%). Three pa-
tients (19%) developed major complications (acute
cholangitis, chest infection, intraoperative ventricular
tachycardia and hypotension). Minor complications
occurred in 2/16 (12%) patients. The mean length of
hospital stay was 11.3 days (range 6-24 days). Three
patients were operated during their second admission.
The mean cost ofover all treatment was Rupees 4,305.
(US $135 approximately).
Table 2 gives a comparative summary of the results
in the two groups.
DISCUSSION
This prospective randomised trial of endoscopic
sphincterotomy followed by surgery (ES+S) versus
surgery alone (SA) in good risk patients with
choledocholithiasis did not reveal any significant
difference in duct clearance, morbidity, hospital stay
and cost between the two groups.
Successful management of CBD stones by ES in a
select group of patients e.g. postcholecystectomy and
high risk patients has prompted some workers2’3 to try
its use for CBD clearance on a routine basis. Retro-
spective analysis of data from the Virginia Mason
Medical Center and the University Hospital of Inns-
bruck, however, indicated no significant difference
in morbidity or mortality in patients managed
endoscopically or surgically. An increased incidence
ofretainedCBD stones was seen after ES as compared
to the surgically treated group; this difference
achieved statistical significance in the report form the
University Hospital of Innsbruck7.
Neoptolemos et al. in a prospective randomized
trial of ES for clearance ofCBD stones prior to open
cholecystectomy versus one time surgical treatment,
found an overall complication rate of 33% and major
complication rate of 16% in the preoperative ES
group, as compared to 22% and 9% respectively in the
surgery alone group. Though the differences did not
achieve significance, a trend towards higher complica-
tion rates in the ES group was noted. The study was
stopped since it was felt that routine preoperative ES
had not offered any significant advantage over con-
ventional therapy.
In another study by the same authors, a higher
complication rate was again found in patients under-
going preoperative ES. Based on multivariate analysis
of risk factors, these investigators recommended that
good risk patients should continue to be treated by one
time surgery and preoperative ES should be reserved
for high risk patients only.
The present trial has also shown that the specific
complications of preoperative ES were of a serious
nature. The overall morbidity in these patients was
greater than those who underwent one time surgical148 R. KAPOOR et al.
treatment, though the diVerences did not reach signifi-
cance levels. Patients in the ES+S group were however
exposed to procedure related morbidity twice and
waited amean of20 days before havingfinal treatment
i.e. cholecystectomy. Study design and predetermined
exclusion criteria resulted in as many as 27 (45%)
patients being excluded from the trial 12 of
these because the stone size was greater than 15 mm.
One time surgical option on the other hand would
have been feasible in all of them. The factors which
excluded use of preoperative ES thus in no way pre-
cluded the institution and/or the outcome of one time
surgical treatment.
Support to our point of view has also come from
Stain et al. who, based on efficacy, morbidity and
cost, did not find preoperative ES for removal,of the
CBD stones to be better than one time surgery. Similar
observations were made by Stiegmann et al. who
showed that there was no added advantage of
precholecystectomy ES in such patients.
The present study did not address the question of
preoperative ES in patients being taken up for
laparoscopic cholecystectomy. There is no consensus
in the available literature on this issue. 1-14 Some ofthe
recent publications
15-17 however do not envisage a
great role for preoperative ES in this setting.
In conclusion, this trial did not support the routine
use of precholecystectomy ES in good risk patients
with choledocholithiasis. This was because in the
precholecystectomy ES group, selection of patients
became mandatory on the basis of past experiences
and definednorms to ensure successful outcome ofES;
because patients in the ES+S group were exposed to
procedure related morbidity twice; and because the
overall results in the ES+S group did not prove to be
better than those in the surgery alone group. More
over, the universal applicability of surgical interven-
tion as compared to selective application of ES re-
mains unmatched.
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